Guggenheim raises target for Elevance Health stock to USD 460

Published on 10/13/2026 at 11:56 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Guggenheim keeps Buy at USD 460. Elevance Health stock trades at EUR 378.15 on October 13, 2026. Results are due October 21, 2026.

Key points in brief

Guggenheim raised its Elevance Health price target from USD 455 to USD 460 on October 12, 2026, while keeping a Buy rating.
Elevance Health reported USD 49.83 billion in second-quarter 2026 revenue and raised adjusted earnings guidance to at least USD 27.00 per share.
The stock was trading at EUR 378.15 at Lang & Schwarz on October 13, 2026 at 11:49 a.m. CEST.
Third-quarter 2026 results are scheduled for October 21, 2026.

Draufsicht-Arrangement mit Aktienzertifikat, ISIN-Karte US2855211023 und Stethoskop — Elevance Health US2855211023 Flatlay mit Aktienzertifikat ISIN-Karte Stethoskop und medizinischen Utensilien auf Marmor, Illustration mit AI erstellt.

Elevance Health (ISIN US0367521038) was trading at EUR 378.15 at Lang & Schwarz on October 13, 2026 at 11:49 a.m. CEST as Guggenheim raised its price target from USD 455 to USD 460 on October 12, 2026. According to Investing.com, the firm kept a Buy rating and pointed to improving performance across Medicaid, Medicare Advantage and Individual ACA businesses.

Three milestones shape the setup

On July 15, 2026, Elevance Health reported second-quarter results ahead of expectations and raised full-year adjusted earnings guidance to at least USD 27.00 per diluted share, according to Business Wire.

On October 1, 2026, the company announced affiliated 2027 Medicare Advantage plans centered on stability, choice and coordinated support, according to Business Wire. On October 12, 2026, Guggenheim lifted its target to USD 460 from USD 455, making the analyst revision the latest dated event in this sequence.

What does the target increase signal?

The target change places valuation emphasis on execution rather than a new corporate transaction. Guggenheim cited pricing and cost initiatives, while its outlook included targeted adjusted earnings per share growth of more than 12 percent in 2027 and beyond, according to Investing.com. That interpretation matters because the company is balancing growth opportunities with medical cost management and investment spending.

A counterweight is Medicare Advantage quality performance. Cantor Fitzgerald maintained an Overweight rating and a USD 450 target after the 2027 Medicare Stars rating fell from 54 percent in 2026 to 47 percent in 2027, according to Investing.com. The figures frame the debate around Elevance Health: adjusted earnings guidance is at least USD 27.00 per share, while Medicare Advantage execution remains a monitored operating issue.

Results date sets the next test

Elevance Health is scheduled to release third-quarter 2026 financial results on October 21, 2026 at 6:00 a.m. EDT, followed by a management webcast at 8:30 a.m. EDT, according to Business Wire. The release will test whether the second-quarter improvement supporting the USD 460 target is visible in reported operating performance.

At Lang & Schwarz, Elevance Health stock was trading at EUR 378.15 on October 13, 2026 at 11:49 a.m. CEST. The further course of trading is shown by the continuously updated real-time quote of Elevance Health stock.